Login / Signup

Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan.

Colin W HowdenErin E CookElyse SwallowKaren YangHelen GuoCorey PelletierRinu JacobKentaro Sugano
Published in: Therapeutic advances in gastroenterology (2023)
-related HCRU, and lower healthcare costs than patients treated with PPI-based therapy.
Keyphrases
  • helicobacter pylori infection
  • helicobacter pylori
  • healthcare
  • protein protein
  • small molecule
  • type diabetes
  • skeletal muscle
  • adipose tissue
  • endoscopic submucosal dissection